Pharma exports to UK may rise up to 10% in FY27 as CETA takes effect

India's pharmaceutical exports to the UK are set to witness substantial growth thanks to the recently negotiated Comprehensive Economic and Trade Agreement. This groundbreaking agreement removes almost all tariffs on Indian drug products, enhancing the competitiveness of Indian generics and finished formulations. Preliminary data indicates promising trends in exports for this fiscal year, solidifying the UK's importance as a critical European market for India's pharmaceutical sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BSWdxhj
via IFTTT

Read More

India-UK FTA projected to boost Indian pharma exports by over 8% to $981 million in FY27: Pharmexcil

Indian pharmaceutical exports to the United Kingdom are projected to grow significantly. The India-UK Comprehensive Economic and Trade Agreement will eliminate tariffs on most products. This pact is expected to enhance the competitiveness of Indian generic medicines in the British market. The agreement also aims to secure supply chains and improve access to affordable medicines.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sOz9NkP
via IFTTT

Read More

NITI Aayog roadmap targets USD 691 bn bioeconomy by 2035; Jitendra Singh says India ready to lead biotech revolution

India's bioeconomy can reach USD 691 billion by 2035, creating millions of high-value jobs. The nation aims to become a top global biotechnology power, driving future growth. A roadmap proposes six National BioMissions and a significant growth fund for development. Talent development, including engineering biology courses, is deemed critical for this ecosystem. This expansion will address national goals like health and food security.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/jUBDlbs
via IFTTT

Read More

Kota kidney damage victims seek euthanasia or treatment in plea to President

Five women demand euthanasia after suffering kidney damage post C-section surgeries. They allege negligence and substandard drugs caused their critical health condition. Families face financial distress as husbands provide constant care for the ailing women. Repeated appeals to officials have yielded no resolution for their urgent medical needs. The petition seeks immediate kidney transplants and compensation or permission for dignified euthanasia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5GPctyg
via IFTTT

Read More

Warburg Pincus buys Mumbai’s pharma company Integrace in Rs 1,200 crore deal

In a landmark transaction, Warburg Pincus, a prominent US private equity firm, has purchased Integrace Private Limited for ₹1,200 crore. With this deal, True North and Temasek Holdings have decided to divest entirely from their stakes in the company. Rehan Khan, a seasoned leader in the industry, will take the helm as CEO, steering Integrace's focus on its celebrated orthopedic and gynecological brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bWKc1ym
via IFTTT

Read More

Jitendra Singh releases Rs 1,500 crore under third phase of Biomedical Research Career Programme

Union Minister Jitendra Singh released fifteen hundred crore rupees for the Biomedical Research Career Programme. This funding supports outstanding biomedical researchers and promotes collaborative research initiatives. The program, initiated in two thousand eight, has supported over five hundred researchers. It has also strengthened research across more than two hundred institutions nationwide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/JrUtK9b
via IFTTT

Read More

Warburg Pincus buys Mumbai’s pharma company Integrace in ₹1,200 crore deal

In a landmark transaction, Warburg Pincus, a prominent US private equity firm, has purchased Integrace Private Limited for ₹1,200 crore. With this deal, True North and Temasek Holdings have decided to divest entirely from their stakes in the company. Rehan Khan, a seasoned leader in the industry, will take the helm as CEO, steering Integrace's focus on its celebrated orthopedic and gynecological brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/xiPgYI4
via IFTTT

Read More